Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development federal funding in FY2024

Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development meeting FY2024

Read the pair as a table intersection. Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development is one side; FY2024 is the other. $2,294,983,342.96 is the obligation total on that intersection and 102 is the year-cell award count. Do not treat $2,343,557,106.30 as a second headline for this year unless the two amounts match. Developer names, product titles, and contract identifiers are unpublished on this packet.

Read /programs/93.360/ (CFDA 93.360) for the program rollup, /fiscal-years/2024/ (FY2024 federal spending) for the year rollup, /programs/ (All programs) for every CFDA hub, and /ties/ (All spending ties) for the rest of the join list. Do not add those pages into $2,294,983,342.96. Recipients are unpublished. One hundred two FY2024 award records against a 130-row program extract is a concentrated BARDA file, not a named-product roster. Other-transaction modifications add rows.

Program extract versus the FY2024 cell

USAspending labels CFDA 93.360 as Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development. That code produced $2,294,983,342.96 when crossed with fiscal year 2024. The program-wide hub does not require a FY2024 filter. The year hub does not require this CFDA. Only this tie applies both filters. The catalog title is BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT. Vaccine versus therapeutic versus diagnostic lines are unpublished inside this year cell. FY2024 figures can still move after deobligations or recoveries.

The program extract-wide obligation total is $2,343,557,106.30 across 130 award records. FY2024 is 97.9% of that book. Other fiscal-year rows for CFDA 93.360 are separate cells. Do not fold /programs/ into this join as if every CFDA were this one. Keep 93.360.

FY2024 as the BARDA countermeasure yearlyTrend cell

An obligation is a legal commitment recorded on an award. An outlay is a payment from the Treasury. $2,294,983,342.96 is the former for BARDA Biodefense Countermeasures in FY2024. Later deobligations, recoveries, or payment schedules can change what leaves the Treasury without this join rewriting itself into a cash register. This page reports $2,294,983,342.96 as given.

102 FY2024 awards are not 102 medical countermeasures

102 is the FY2024 award-record count published on this pair. 130 is the program-extract award-record count across years. Dividing $2,294,983,342.96 by 130 would mix a one-year dollar total with a multi-year row count, so this page does not publish that ratio as a typical award. Unique recipients are unpublished. One hundred two FY2024 award records against a 130-row program extract is a concentrated BARDA file, not a named-product roster. Other-transaction modifications add rows.

Developer rankings this BARDA year cell cannot support

Budget justifications, program evaluation reports, and press releases answer other questions. They are not the source of this cell. If a chart mixes an NIH intramural overlay, a named-manufacturer list, or an outlay register with CFDA 93.360 in FY2024, the chart has left this join. Developer names, product titles, and contract identifiers are unpublished on this packet.

Cite USAspending.gov: Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development (CFDA 93.360) obligated $2,294,983,342.96 in FY2024. Name Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development and FY2024 together. Keep the obligation word. If /programs/93.360/ or /fiscal-years/2024/ has refreshed, prefer the live hub over this snapshot for current rows. The pair is not a MCM catalog, a lot-release log, or a cash-draw file. 97.9% of $2,343,557,106.30 is the program share on this packet, not a budget score.

Where to read CFDA 93.360 and FY2024 next

Open /programs/93.360/ for CFDA 93.360, /fiscal-years/2024/ for FY2024 federal spending, /programs/ (All programs) for other catalog lines, and /ties/ (All spending ties) for other pairs. None of those links convert this cell into an NIH intramural overlay, a named-manufacturer list, or an outlay register, into outlays this packet omits, or into a contractor list. Cite both sides: Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development and FY2024, $2,294,983,342.96, USAspending.gov, obligations only.

Questions

How much did Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development show in federal obligations in FY2024?

USAspending.gov records $2,294,983,342.96 in Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development obligations for FY2024 (CFDA 93.360) across 102 awards. That is an obligation aggregate for the pair, not an outlay and not the program-wide $2,343,557,106.30.

Is BARDA Biodefense Countermeasures FY2024 cash already paid to manufacturers?

No. $2,294,983,342.96 is a yearlyTrend obligation sum, not an outlay. Payments from the Treasury can lag or differ. This packet has no outlay total for Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development in FY2024.

Do 102 awards mean 102 BARDA products?

No. 102 is the FY2024 award-record count on this pair, not a published unique-recipient census. The program extract lists 130 awards across years. Modifications can add rows. Original filings remain on USAspending.gov. Keep both the CFDA number and the fiscal year in the citation.

Which pages parent Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development and FY2024?

The CFDA 93.360 hub is the program parent. The FY2024 federal-spending hub is the year parent. All programs lists CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Biomedical Advanced Research And Development Authority (Barda), Biodefense Medical Countermeasure Development × FY2024 at $2,294,983,342.96.